RT Journal Article
SR Electronic
T1 Comorbidity accounts for severe COVID-19 risk, but how do we measure it? Retrospective assessment of the performance of three measures of comorbidity using 4,607 hospitalizations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.02.21259898
DO 10.1101/2021.07.02.21259898
A1 Monterde, David
A1 Carot-Sans, Gerard
A1 Cainzos-Achirica, Miguel
A1 Abilleira, Sònia
A1 Coca, Marc
A1 Vela, Emili
A1 Clèries, Montse
A1 Valero, Damià
A1 Comin-Colet, Josep
A1 Garcia-Eroles, Luis
A1 Sust, Pol Perez
A1 Arrufat, Miquel
A1 Lejardi, Yolanda
A1 Piera, Jordi
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.07.02.21259898.abstract
AB Background Comorbidity burden has been identified as a relevant predictor of critical illness in patients hospitalized with coronavirus disease 2019 (COVID-19). However, comorbidity burden is often represented by a simple count of few conditions that may not fully capture patients’ complexity.Purpose To evaluate the performance of a comprehensive index of the comorbidity burden (Queralt DxS), which includes all chronic conditions present on admission, as an adjustment variable in models for predicting critical illness in hospitalized COVID-19 patients and compare it with two broadly used measures of comorbidity.Patients and methods We analyzed data from all COVID-19 hospitalizations reported in eight public hospitals of Catalonia (North-East Spain) between June 15 and December 8 2020. The primary outcome was a composite of critical illness that included the need for invasive mechanical ventilation, transfer to ICU, or in-hospital death. Predictors included age, sex, and comorbidities present on admission measured using three indices: the Charlson index, the Elixhauser index, and the Queralt DxS index for comorbidities on admission. The performance of different fitted models was compared using various indicators, including the area under the receiving operating characteristics curve (AUC).Results Our analysis included 4,607 hospitalized COVID-19 patients. Of them, 1,315 experienced critical illness. Comorbidities significantly contributed to predicting the outcome in all summary indices used. The AUC for prediction of critical illness was 0.641 (95% CI 0.624-0.660) for the Charlson index, 0.665 (0.645-0.681) for the Elixhauser index, and 0.787 (0.773-0.801) for Queralt DxS. Other metrics of model performance also showed Queralt DxS being consistently superior to the other indices.Conclusion In our analysis, the ability of comorbidity indices to predict hospital outcomes in hospitalized COVID-19 patients increased with their exhaustivity. The comprehensive Queralt DxS index may improve the accuracy of predictive models for resource allocation and clinical decision-making in the hospital setting.Competing Interest StatementDavid Monterde declares that he is the developer of the Queralt System. This tool is available online for research purposes at no cost. The author reports no other conflicts of interest in this work, which did not receive specific funding.Clinical TrialNAFunding StatementThis study did not receive specific fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The independent ethics committee of the Bellvitge Biomedical Research Institute (IDIBELL) approved the study protocol and waived the need for informed consent, as the data were generated as part of routine clinical care and fully de-identified for analytic purposes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly accessible but are available from the corresponding author upon reasonable request.AICAkaike information criterionAUCPRarea under the precision-recallAUCROCarea under the receiving operating characteristicsCIconfidence intervalCMclinical modificationCOVID-19coronavirus disease 2019ICDinternational classification of diseasesICSCatalan institute of healthICUintensive care unitIQRinterquartile range